

REMARKS

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, enclosed herewith is a diskette containing the Sequence Listing for this application in computer readable form (CRF) in compliance with 37 C.F.R. §§ 1.821-1.825.

Specifically, the Sequence Listing submitted herewith corrects the following defects as outlined below:

1) The Raw Sequence Listing Error Report indicated that in SEQ ID Nos. 9-13, <220> through <223> were missing pursuant to §1.823 of the Sequence Rules. Applicants believe they have corrected the Sequence Listing as indicated in the Raw Sequence Listing Error Summary.

2) The Raw Sequence Listing Error Report indicated that use of "N" had been detected in the Sequence Listing.

The Sequence Listing is corrected herein to identify "N" as G, A, C or T(U). Applicants point out that PatentIn, the program utilized to generate the original Sequence Listing for this application, used the nucleotide symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. On page 100 of the PatentIn User Manual (November 1990), "N" is identified as being "G, A, C or T(U)." Further, this usage is in compliance with current rules of practice (see 37 C.F.R. § 1.822(b)). Thus applicants believe that "n" has been properly identified by accepted nomenclature and this correction constitutes no new matter.

Applicants believe they have corrected the Sequence Listing as indicated in the Raw Sequence Listing Error Summary. Thus applicants believe that the Sequence Listing is in proper condition for consideration.

ATTORNEY DOCKET NO. 14114.0325U2
SERIAL NO. 09/674,195

Therefore, applicants resubmit herewith a diskette containing the corrected Sequence Listing for this application in computer readable form (CRF) and a paper copy of the corrected Sequence Listing in compliance with 37 C.F.R. §§1.821-1.825. Applicants hereby certify that the information in both the computer readable form and the paper copy of the Sequence Listing as filed with this application is the same and includes no new matter.

No additional fee is believed due, however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,



Gwendolyn D. Spratt
Registration No. 36,016

The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
(404) 688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on the date shown below.



Gwendolyn D. Spratt

11-18-02

Date